From Pathophysiological Hypotheses to Case-Control Study Design: Resistance from Antibiotic Exposure in Community-Onset Infections

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2022 Feb 25

PMID 35203803

Authors

Salam Abbara

Didier Guillemot

Christian Brun-Buisson

Laurence Watier

Affiliations

Soon will be listed here.

Abstract

Antimicrobial resistance is a global public health concern, at least partly due to the misuse of antibiotics. The increasing prevalence of antibiotic-resistant infections in the community has shifted at-risk populations into the general population. Numerous case-control studies attempt to better understand the link between antibiotic use and antibiotic-resistant community-onset infections. We review the designs of such studies, focusing on community-onset bloodstream and urinary tract infections. We highlight their methodological heterogeneity in the key points related to the antibiotic exposure, the population and design. We show the impact of this heterogeneity on study results, through the example of extended-spectrum β-lactamases producing Enterobacteriaceae. Finally, we emphasize the need for the greater standardization of such studies and discuss how the definition of a pathophysiological hypothesis specific to the bacteria-resistance pair studied is an important prerequisite to clarify the design of future studies.

References

Rodriguez-Bano J, Picon E, Gijon P, Hernandez J, Ruiz M, Pena C . Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2009; 50(1):40-8. DOI: 10.1086/649537. View

Zhu F, Rodado M, Asmar B, Salimnia H, Thomas R, Abdel-Haq N . Risk factors for community acquired urinary tract infections caused by extended spectrum β-lactamase (ESBL) producing in children: a case control study. Infect Dis (Lond). 2019; 51(11-12):802-809. DOI: 10.1080/23744235.2019.1654127. View

Hsieh C, Shen Y, Hwang K . Clinical implications, risk factors and mortality following community-onset bacteremia caused by extended-spectrum β-lactamase (ESBL) and non-ESBL producing Escherichia coli. J Microbiol Immunol Infect. 2011; 43(3):240-8. DOI: 10.1016/S1684-1182(10)60038-2. View

Kim M, Song K, Kim C, Choe P, Beom Park W, Bang J . Clinical Prediction Score for Community-Onset Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase-Producing and Species. J Korean Med Sci. 2019; 34(14):e116. PMC: 6460111. DOI: 10.3346/jkms.2019.34.e116. View

Jacmel L, Timsit S, Ferroni A, Auregan C, Angoulvant F, Cheron G . Extended-spectrum β-lactamase-producing bacteria caused less than 5% of urinary tract infections in a paediatric emergency centre. Acta Paediatr. 2016; 106(1):142-147. DOI: 10.1111/apa.13546. View

Lee S, Woo Han S, Kim K, Song D, Kwon K . Third-generation cephalosporin resistance of community-onset Escherichia coli and Klebsiella pneumoniae bacteremia in a secondary hospital. Korean J Intern Med. 2014; 29(1):49-56. PMC: 3932395. DOI: 10.3904/kjim.2014.29.1.49. View

Chaniotaki S, Giakouppi P, Tzouvelekis L, Panagiotakos D, Kozanitou M, Petrikkos G . Quinolone resistance among Escherichia coli strains from community-acquired urinary tract infections in Greece. Clin Microbiol Infect. 2004; 10(1):75-8. DOI: 10.1111/j.1469-0691.2004.00807.x. View

Goulenok T, Ferroni A, Bille E, Lecuyer H, Join-Lambert O, Descamps P . Risk factors for developing ESBL E. coli: can clinicians predict infection in patients with prior colonization?. J Hosp Infect. 2013; 84(4):294-9. DOI: 10.1016/j.jhin.2013.04.018. View

Pirofski L, Casadevall A . The meaning of microbial exposure, infection, colonisation, and disease in clinical practice. Lancet Infect Dis. 2002; 2(10):628-35. DOI: 10.1016/s1473-3099(02)00398-5. View

10.

Killgore K, March K, Guglielmo B . Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother. 2004; 38(7-8):1148-52. DOI: 10.1345/aph.1D622. View

11.

Albaramki J, Abdelghani T, Dalaeen A, Khdair Ahmad F, Alassaf A, Odeh R . Urinary tract infection caused by extended-spectrum β-lactamase-producing bacteria: Risk factors and antibiotic resistance. Pediatr Int. 2019; 61(11):1127-1132. DOI: 10.1111/ped.13911. View

12.

Harris A, Samore M, Carmeli Y . Control group selection is an important but neglected issue in studies of antibiotic resistance. Ann Intern Med. 2000; 133(2):159. DOI: 10.7326/0003-4819-133-2-200007180-00018. View

13.

Rodriguez-Bano J, Alcala J, Cisneros J, Grill F, Oliver A, Horcajada J . Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008; 168(17):1897-902. DOI: 10.1001/archinte.168.17.1897. View

14.

Castillo-Tokumori F, Irey-Salgado C, Malaga G . Worrisome high frequency of extended-spectrum beta-lactamase-producing Escherichia coli in community-acquired urinary tract infections: a case-control study. Int J Infect Dis. 2016; 55:16-19. DOI: 10.1016/j.ijid.2016.12.007. View

15.

Kim H, Kim Y, Park Y, Choi M, Lee G, Lee K . Risk Factors and Molecular Features of Sequence Type (ST) 131 Extended-spectrum β-Lactamase-producing Escherichia coli in Community-onset Bacteremia. Sci Rep. 2017; 7(1):14640. PMC: 5677100. DOI: 10.1038/s41598-017-14621-4. View

16.

Friedman N, Kaye K, Stout J, McGarry S, Trivette S, Briggs J . Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002; 137(10):791-7. DOI: 10.7326/0003-4819-137-10-200211190-00007. View

17.

Colodner R, Kometiani I, Chazan B, Raz R . Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Infection. 2008; 36(1):41-5. DOI: 10.1007/s15010-007-7083-y. View

18.

Fan N, Chen H, Chen C, Ou L, Lin T, Tsai M . Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children. J Microbiol Immunol Infect. 2013; 47(5):399-405. DOI: 10.1016/j.jmii.2013.05.006. View

19.

Pilmis B, Monnier A, Zahar J . Gut Microbiota, Antibiotic Therapy and Antimicrobial Resistance: A Narrative Review. Microorganisms. 2020; 8(2). PMC: 7074698. DOI: 10.3390/microorganisms8020269. View

20.

Glaser P, Martins-Simoes P, Villain A, Barbier M, Tristan A, Bouchier C . Demography and Intercontinental Spread of the USA300 Community-Acquired Methicillin-Resistant Staphylococcus aureus Lineage. mBio. 2016; 7(1):e02183-15. PMC: 4752609. DOI: 10.1128/mBio.02183-15. View